Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
This article was originally published in The Pink Sheet Daily
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
You may also be interested in...
Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.